FAQs FOR Melanotan-1 (MT-1)
Melanotan-1 (MT-1)
Melanotan-1 (MT-1), also known scientifically as afamelanotide, is a synthetic analogue of alpha-melanocyte-stimulating hormone (α-MSH) that activates melanocortin receptors involved in melanin production.
The medically developed form, afamelanotide, has an established clinical use for erythropoietic protoporphyria (EPP), a rare disorder in which exposure to light can cause severe phototoxic reactions. Afamelanotide is administered as a controlled-release implant under the brand Scenesse.
Unapproved products marketed as “Melanotan-1” or “MT-1” are also available through online research-chemical markets, but these products should not be confused with the regulated pharmaceutical formulation.
Mechanism of Action
MT-1 is structurally related to α-MSH and acts primarily through the melanocortin-1 receptor (MC1R).
- MC1R Activation: MT-1 binds to MC1R receptors located on melanocytes, the cells responsible for producing melanin.
- Melanin Production: MC1R activation stimulates intracellular signaling that increases melanin synthesis, particularly the production of eumelanin, the darker form of melanin.
- Pigmentation: Increased melanin production can result in greater skin pigmentation.
- Photoprotection: In its approved pharmaceutical application, increased eumelanin is used as part of the body’s protective response to light exposure.
- Greater Stability: Compared with naturally occurring α-MSH, afamelanotide was engineered to have greater resistance to enzymatic degradation, allowing it to remain biologically active for longer.
Melanotan-1 and Melanin
The primary biological interest in MT-1 is its ability to stimulate melanogenesis.
When MC1R is activated, melanocytes increase the synthesis of melanin through a signaling pathway involving cyclic AMP (cAMP) and downstream melanogenic enzymes such as tyrosinase.
This distinguishes MT-1 from conventional tanning approaches, which generally rely on ultraviolet exposure to stimulate the skin’s pigment-producing response.
However, increased pigmentation does not mean that ultraviolet exposure becomes harmless. Melanin provides some natural photoprotective effects, but it does not replace appropriate UV protection.
Medical Application
The best-established medical application of afamelanotide is erythropoietic protoporphyria (EPP).
EPP is a rare inherited disorder involving abnormal accumulation of protoporphyrin, which can make exposed skin extremely sensitive to light. Patients may experience intense burning pain and other phototoxic reactions after exposure.
Afamelanotide increases eumelanin production and can increase the skin’s tolerance to light exposure in people with EPP.
MT-1 vs. Unapproved Melanotan Products
There is an important distinction between pharmaceutical afamelanotide and products sold online under names such as “Melanotan-1.”
| Characteristic | Pharmaceutical Afamelanotide | Unapproved MT-1 Products |
|---|---|---|
| Active compound | Afamelanotide | Products may claim to contain MT-1 |
| Medical development | Yes | No |
| Controlled manufacturing | Yes | Variable |
| Established medical indication | EPP | No established approved indication |
| Regulatory oversight | Pharmaceutical regulation | Often marketed as research products |
| Quality assurance | Controlled | May vary considerably |
An online product labeled “MT-1” should therefore not automatically be assumed to have the same purity, identity, sterility, formulation, or clinical characteristics as pharmaceutical afamelanotide.
Research Areas
Beyond its established medical application, melanocortin receptor signaling has been investigated in relation to:
- Melanogenesis
- Skin pigmentation
- Photoprotection
- Melanocyte biology
- Inflammatory signaling
- Oxidative stress
- Melanocortin receptor pharmacology
Research into these mechanisms continues to contribute to understanding how melanocortin pathways regulate pigmentation and other physiological processes.
Safety Considerations
Afamelanotide has been studied clinically, but its medical use is different from the use of unapproved MT-1 products.
Potential adverse effects associated with melanocortin stimulation or afamelanotide treatment can include:
- Nausea
- Headache
- Fatigue
- Dizziness
- Changes in skin pigmentation
- Injection or implant-site reactions
- Darkening of existing pigmented lesions
Because melanocortin stimulation can alter pigmentation, changes in existing moles or other pigmented lesions require appropriate medical evaluation.
Unregulated products introduce additional concerns because their actual composition, purity, sterility, and concentration may not be independently verified.
Regulatory Status
Afamelanotide is an established pharmaceutical treatment for EPP in certain regulatory jurisdictions. The medical formulation should not be equated with unapproved MT-1 products sold online for tanning or cosmetic purposes.
Unapproved Melanotan-1 products are not established treatments for cosmetic tanning or general health purposes, and their quality and safety can vary substantially.
Summary
Melanotan-1 (MT-1) is a synthetic α-MSH analogue that primarily acts through the MC1R receptor on melanocytes, stimulating eumelanin production and increasing pigmentation.
Its most established medical application is afamelanotide for erythropoietic protoporphyria, where increased melanin production can help improve tolerance to light exposure.
The term “MT-1” is also used commercially for unapproved research products. These should be distinguished from pharmaceutical afamelanotide because regulatory status, manufacturing standards, purity, formulation, and clinical evidence are not necessarily equivalent.